AER004

N/A

Report date: 2023/10/20 14:37:34

Base Information

Drug NameAER004
Drug Alias NameAER004AER-004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Angiotensin-converting enzyme 2SARS-CoV-2 Spike glycoprotein receptor binding domain modulators
TargetsAngiotensin-converting enzyme 2SARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAerium Therapeutics IncThe Rockefeller University
China Registration ClassN/A

Develop Information

Active CompaniesAerium Therapeutics IncThe Rockefeller University
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A